Meeting
2023 ASCO Gastrointestinal Cancers Symposium
A phase 1b, open-label, safety, pharmacokinetic, and pharmacodynamic study of an anti–super-enhancer triptolide analogue with nab-paclitaxel plus gemcitabine in patients with metastatic adenocarcinoma of the pancreas.
Authors
Joon Oh Park
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea;
Joon Oh Park , Jung Yong Hong , Seung Tae Kim , Young Suk Park , Ashok Saluja
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05557851
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS769)
DOI
10.1200/JCO.2023.41.4_suppl.TPS769
Abstract #
TPS769
Poster Bd #
Q5
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine-refractory metastatic pancreatic cancer patients.
First Author: Esther Pijnappel
Poster
2014 Gastrointestinal Cancers Symposium
Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).
First Author: Eileen Mary O'Reilly
Poster
2020 ASCO Virtual Scientific Program
Phase II, open-label, randomized study of first-line zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in Claudin 18.2–positive metastatic pancreatic cancer (mPC).
First Author: Wungki Park
Poster
2020 ASCO Virtual Scientific Program
A single-arm, open-label, phase I study of CPI-613 (Devimistat) in combination with gemcitabine and nab-paclitaxel for patients with locally advanced or metastatic pancreatic adenocarcinoma.
First Author: Angela Tatiana Alistar